



Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.

## DRUG POLICY

# Doptelet (avatrombopag)

### NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

### BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

### DESCRIPTION

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-Approved Indications

1. Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD):  
Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
2. Treatment of Thrombocytopenia in Patients with Chronic Immune Thrombocytopenia (ITP):  
Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
3. Treatment of Thrombocytopenia in Pediatric Patients with Persistent or Chronic Immune Thrombocytopenia (ITP):  
Doptelet is indicated for the treatment of thrombocytopenia in patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

### POLICY

#### Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- A. Thrombocytopenia in chronic liver disease: pretreatment platelet count
- B. Immune thrombocytopenia: pretreatment and current platelet counts

#### Exclusions

Coverage will not be provided for members with the following exclusion:

- Concomitant use of the requested drug with other thrombopoietin receptor agonists (e.g., Alvaiz, Promacta, Nplate, Mulpleta), or with spleen tyrosine kinase inhibitors (e.g., Tavalisse), or with Bruton's tyrosine kinase inhibitors (e.g., Wayrizl).

#### Preferred Drug Plan Design

Member must meet BOTH the Preferred Drug Plan Design and the Criteria for Initial Approval/Continuation of Therapy when both are applicable.

Criteria for initial approval for Doptelet will only apply when one of the following criteria are met:

- A. Member has had an inadequate response to treatment or intolerable adverse event with Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).
- B. Member has a clinical reason to avoid Alvaiz (eltrombopag choline) and eltrombopag olamine (generic Promacta).
- C. Member is currently receiving treatment with the requested product through insurance (excludes obtainment as samples or via manufacturer's patient assistance programs) and experiencing a positive therapeutic outcome.

#### Prescriber Specialties

- A. For diagnosis of chronic immune thrombocytopenia, this medication must be prescribed by or in consultation with a hematologist.
- B. For diagnosis of thrombocytopenia in patients with chronic liver disease, this medication must be prescribed by or in consultation with a hematologist, hepatologist or gastroenterologist.

#### Criteria for Initial Approval

##### **A. Thrombocytopenia in chronic liver disease**

Authorization of 30 days may be granted for treatment of thrombocytopenia in members with chronic liver disease when both of the following criteria are met:

1. Member has an untransfused platelet count of less than  $50 \times 10^9/L$  taken within 14 days of the request.
2. Member is scheduled to undergo a procedure.

##### **B. Chronic immune thrombocytopenia (ITP)**

Authorization of 6 months may be granted for treatment of chronic ITP when both of the following criteria are met:

1. Inadequate response or intolerance to prior therapy (for example, corticosteroids or immunoglobulins).
2. Untransfused platelet count at any point prior to the initiation of the requested medication is less than  $30 \times 10^9/L$  OR  $30 \times 10^9/L$  to  $50 \times 10^9/L$  with symptomatic bleeding (e.g., significant mucous membrane bleeding, gastrointestinal bleeding or trauma) or risk factors for bleeding (see Appendix).

### Continuation of Therapy

#### **A. Thrombocytopenia in chronic liver disease**

Continuation of therapy, defined as use beyond the initial approval for same procedure, is not approvable. All members (including new members) requesting authorization due to newly scheduled procedure must meet all initial authorization criteria.

#### **B. Chronic ITP**

1. Authorization of 3 months may be granted to members with current platelet count less than  $50 \times 10^9/L$  for whom the platelet count is not sufficient to prevent clinically important bleeding and who have not received a maximal Doptelet dose for at least 4 weeks.
2. Authorization of 12 months may be granted to members with current platelet count less than  $50 \times 10^9/L$  for whom the current platelet count is sufficient to prevent clinically important bleeding.
3. Authorization of 12 months may be granted to members with current platelet count of  $50 \times 10^9/L$  to  $200 \times 10^9/L$ .
4. Authorization of 12 months may be granted to members with current platelet count greater than  $200 \times 10^9/L$  to less than or equal to  $400 \times 10^9/L$  for whom Doptelet dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.

Doptelet (avatrombopag) is considered **not medically necessary** for members who do not meet the criteria set forth above.

### Other

*Members currently receiving the requested medication as samples or via the manufacturer's patient assistance program will be required to meet the criteria for initial approval. This ensures that members are treated equally regardless of their provider's ability to access medication samples.*

### Appendix

#### **Examples of risk factors for bleeding (not all inclusive)**

- Undergoing a medical or dental procedure where blood loss is anticipated
- Comorbidity (e.g., peptic ulcer disease, hypertension)
- Mandated anticoagulation therapy
- Profession (e.g., construction worker) or lifestyle (e.g., plays contact sports) that predisposes patient to trauma

### Non-Formulary Exception Criteria

Non-Formulary Exception criteria applies to formularies which do not include the requested product(s) on the formulary drug list. Meeting the criteria above may satisfy some, or all, portions of the Non-Formulary Exception Criteria. A medication that is non-formulary may be covered when the Criteria for Approval AND the following criteria are met:

1. The requested drug must be used for an FDA-approved indication, or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines). Diagnostic testing/lab results required when applicable.
2. The prescribed dose/quantity must fall within the FDA-approved labeling or dosing guidelines found in the compendia of current literature.
3. All covered formulary alternative drugs on any tier will be ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would have adverse effects. Documentation is

required and must include chart note(s) or other documentation indicating prior treatment failure, severity of the adverse event (if any), and dosage and duration of the prior treatment, or contraindication to formulary alternatives.

#### Dosing and Administration

Approvals may be subject to age and dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

#### Quantity Limit

- CLD: 3 tablets per day
- ITP: 2 tablets per day

### PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT\* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

- Not applicable

### REFERENCES

- Doptelet [package insert]. Durham, NC: AkaRx, Inc.; July 2024.
- Jurczak W, Chojnowski K, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. [Br J Haematol.](#) 2018;183(3):479-490.
- Nuenert C, Terrel DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv* 2019;3(23):3829–3866.
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv* 2019;3(22): 3780–3817.
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood.* 2009;113(11):2386-2393.

### POLICY HISTORY

**Policy #:** 05.04.46

**Original Effective Date:** March 13, 2022

**Reviewed:** October 2025

**Revised:** October 2025

**Current Effective Date:** January 1, 2026